


SARS-CoV-2-IN-13

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 56961-10-5 |
| Formula: | C ₁₃ H ₈ Cl ₂ N ₂ O ₄ |
| Molecular Weight: | 327.12 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|----------------------------|---|
| Description | SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide, displaying greater stability in human plasma and liver S9 enzymes assay. It improves bioavailability and half-life when administered orally and is a potent SARS-CoV-2 inhibitor with an IC ₅₀ of 0.057 μM [1]. |
| Targets(IC ₅₀) | SARS-CoV |

Solubility Information

| | |
|------------|--|
| Solubility | DMSO: 112.5 mg/mL (343.91 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|--|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 3.057 mL | 15.2849 mL | 30.5698 mL |
| 5 mM | 0.6114 mL | 3.057 mL | 6.114 mL |
| 10 mM | 0.3057 mL | 1.5285 mL | 3.057 mL |
| 50 mM | 0.0611 mL | 0.3057 mL | 0.6114 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481